RESUMEN
Liddle syndrome is an autosomal dominant form of monogenic hypertension that is caused by mutations in SCNN1A, SCNN1B or SCNN1G, which respectively encode the α, ß and γ subunits of the epithelial sodium channel. In the present study, DNA was extracted from leukocytes in peripheral blood obtained from all members of a family with Liddle syndrome. Wholeexome sequencing and Sanger sequencing were performed to assess the candidate variant and a cosegregation analysis was conducted. A frameshift mutation in SCNN1B (NM_ 000336: c.1806dupG, p.Pro603Alafs*5) in the family was identified, characterized by earlyonset hypertension and hypokalemia. The mutation led to the truncation of the ß subunit of the epithelial sodium channel and a lack of the conservative PY motif. Furthermore, a systematic review of followup data from patients with Liddle syndrome with SCNN1B mutations was performed. The followup data of 108 patients with pathogenic SCNN1B mutations from 47 families were summarized. Phenotypic heterogeneity was evident in patients with Liddle syndrome and earlyonset hypertension was the most frequent symptom. Patients responded well to targeted amiloride therapy with significant improvements in blood pressure and serum potassium concentration. The present study demonstrates that confirmatory genetic testing and targeted therapy can prevent premature onset of clinical endpoint events in patients with Liddle syndrome.
Asunto(s)
Hipertensión , Síndrome de Liddle , Humanos , Síndrome de Liddle/diagnóstico , Síndrome de Liddle/genética , Síndrome de Liddle/tratamiento farmacológico , Canales Epiteliales de Sodio/genética , Mutación del Sistema de Lectura , Mutación , Hipertensión/genética , Hipertensión/tratamiento farmacológico , PotasioRESUMEN
The objective of this study was to clinically and genetically characterize a pedigree with Liddle syndrome (LS). A LS pedigree comprising with one proband and seven family members was enrolled. The subjects' symptoms, laboratory results and genotypes were analyzed. Peripheral venous samples were collected from the subjects, and genomic DNA was extracted. DNA library construction and exome capture were performed on an Illumina HiSeq 4000 platform. The selected variant sites were validated using Sanger sequencing. The mutation effects were investigated using prediction tools. The proband and her paternal male family members had mild hypertension, hypokalemia and muscle weakness, including the absence of low renin and low aldosterone. Genetic analysis revealed that the proband carried a compound heterozygous mutation in SCNN1A, a novel heterozygous mutation, c.1130T > G (p.Ile377Ser) and a previously characterized polymorphism, c.1987A > G (p.Thr633Ala). The novel mutation site was inherited in an autosomal dominant manner and was predicted by in silico tools to exert a damaging effect. Alterations in the SCNN1A domain were also predicted by protein structure modeling. After six months of follow-up, treatment had significantly improved the patient's limb weakness and electrolyte levels. The novel mutation c.1130T > G of the SCNN1A gene was detected in the pedigree with LS. The clinical manifestations of the pedigree were described, which expand the phenotypic spectrum of LS. This result of this study also emphasizes the value of genetic testing for diagnosing LS.
Asunto(s)
Hipertensión , Hipopotasemia , Síndrome de Liddle , Femenino , Humanos , Masculino , Hipopotasemia/genética , Canales Epiteliales de Sodio/genética , Canales Epiteliales de Sodio/uso terapéutico , Hipertensión/genética , Síndrome de Liddle/diagnóstico , Síndrome de Liddle/tratamiento farmacológico , Síndrome de Liddle/genética , Mutación , LinajeRESUMEN
PURPOSE: Through describing the confusing misdiagnosis process of Liddle syndrome, we try to reveal the importance of accurate aldosterone-renin detection and a genetic test for Liddle syndrome. METHODS: We found a family of hypertension and hypokalaemia with the proband of a 21-year-old female who had been misdiagnosed as primary aldosteronism (PA). She presented with high aldosterone and low renin levels. Aldosterone is not suppressed in the saline infusion test and captopril challenge test. However, treatment with a standard dose of spironolactone has no blood pressure improvement effect. A heterozygous variant of SCNN1G was found with whole exome sequencing and Liddle syndrome is indicated. Treatment with amiloride was effective. We rechecked aldosterone-renin levels with two different aldosterone and renin test kits. Clinical features and the mutant gene SCNN1G of each family member were determined by the Sanger method. RESULTS: The two kits had nearly opposite results. Among those Liddle syndrome patients confirmed by a genetic test, for Test kit A all ARR were screened positive while for test kit B negative. It seems Test kit B is consistent with the diagnosis while test kit A misleads the diagnosis. A novel SCNN1G mutation, c.1729 C > T, was found in this family, which introduce a premature stop codon in the γ subunit in the epithelial Na+ channel (ENaC) and resulted in a deletion of 72 amino acids at the carboxyl end. CONCLUSION: inaccurate ARR detection might misdiagnose Liddle syndrome. A Gene test is an important method for the diagnosis of Liddle syndrome. A novel SCNN1G missense mutation, c.1729 C > T, is found in a Chinese family.
Asunto(s)
Hiperaldosteronismo , Hipertensión , Síndrome de Liddle , Adulto , Aldosterona , Quimosina/genética , Quimosina/metabolismo , Errores Diagnósticos , Canales Epiteliales de Sodio/genética , Canales Epiteliales de Sodio/metabolismo , Canales Epiteliales de Sodio/uso terapéutico , Femenino , Humanos , Hiperaldosteronismo/diagnóstico , Hiperaldosteronismo/genética , Hipertensión/diagnóstico , Hipertensión/tratamiento farmacológico , Hipertensión/genética , Síndrome de Liddle/diagnóstico , Síndrome de Liddle/tratamiento farmacológico , Síndrome de Liddle/genética , Mutación , Renina , Adulto JovenRESUMEN
BACKGROUND: Liddle syndrome is a monogenic disease with autosomal dominant inheritance. Basic characteristics of this disease are hypertension, reduced concentration of aldosterone and renin activity, as well as increased excretion of potassium leading to low level of potassium in serum and metabolic alkalosis. The cause of Liddle syndrome is missense or frameshift mutations in SCNN1A, SCNN1B, or SCNN1G genes that encode epithelial sodium channel subunits. CASE PRESENTATION: We describe a family with Liddle syndrome from Russia. 15-year-old proband has arterial hypertension, hypokalemia, hyporeninemia, metabolic alkalosis, but aldosterone level is within the normal range. At 12 years of age, arterial hypertension was noticed for the first time. We identified novel frameshift mutation c.1769delG (p.Gly590Alafs) in SCNN1G, which encodes the γ subunit of ENaC in vertebrates. The father and younger sister also harbor this heterozygous deletion. Treatment with amiloride of proband and his sister did not normalize the blood pressure, but normalized level of plasma renin activity. CONCLUSIONS: Our results expand the mutational spectrum of Liddle syndrome and provide further proof that the conserved PY motif is crucial to control of ENaC activity. Genetic analysis has implications for the management of hypertension, specific treatment with amiloride and counselling in families with Liddle syndrome.
Asunto(s)
Canales Epiteliales de Sodio/genética , Síndrome de Liddle/genética , Adolescente , Amilorida/uso terapéutico , Presión Sanguínea , Bloqueadores del Canal de Sodio Epitelial/uso terapéutico , Femenino , Mutación del Sistema de Lectura , Heterocigoto , Humanos , Síndrome de Liddle/tratamiento farmacológico , Síndrome de Liddle/fisiopatología , Masculino , Persona de Mediana Edad , Linaje , Renina/sangre , Federación de RusiaRESUMEN
BACKGROUND: Liddle syndrome (LS) is an autosomal dominant disorder caused by single-gene mutations of the epithelial sodium channel (ENaC). It is characterized by early-onset hypertension, spontaneous hypokalemia and low plasma renin and aldosterone concentrations. In this study, we reported an LS pedigree with normokalemia resulting from a novel SCNN1G frameshift mutation. METHODS: Peripheral blood samples were collected from the proband and eight family members for DNA extraction. Next-generation sequencing and Sanger sequencing were performed to identify the SCNN1G mutation. Clinical examinations were used to comprehensively evaluate the phenotypes of two patients. RESULTS: Genetic analysis identified a novel SCNN1G frameshift mutation, p.Arg586Valfs*598, in the proband with LS. This heterozygous frameshift mutation generated a premature stop codon and deleted the vital PY motif of ENaC. The same mutation was present in his elder brother with LS, and his mother without any LS symptoms. Biochemical examination showed normokalemia in the three mutation carriers. The mutation identified was not found in any other family members, 100 hypertensives, or 100 healthy controls. CONCLUSIONS: Our study identified a novel SCNN1G frameshift mutation in a Chinese family with LS, expanding the genetic spectrum of SCNN1G. Genetic testing helped us identify LS with a pathogenic mutation when the genotypes and phenotype were not completely consistent because of the hypokalemia. This case emphasizes that once a proband is diagnosed with LS by genetic testing, family genetic sequencing is necessary for early diagnosis and intervention for other family members, to protect against severe cardiovascular complications.
Asunto(s)
Canales Epiteliales de Sodio/genética , Mutación del Sistema de Lectura , Hipertensión/genética , Síndrome de Liddle/genética , Potasio/sangre , Adolescente , Anciano , Amilorida/uso terapéutico , Antihipertensivos/uso terapéutico , Biomarcadores/sangre , Presión Sanguínea , Niño , Combinación de Medicamentos , Femenino , Predisposición Genética a la Enfermedad , Herencia , Humanos , Hidroclorotiazida/uso terapéutico , Hipertensión/tratamiento farmacológico , Hipertensión/fisiopatología , Síndrome de Liddle/sangre , Síndrome de Liddle/diagnóstico , Síndrome de Liddle/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Linaje , Fenotipo , Resultado del Tratamiento , Adulto JovenRESUMEN
Liddle syndrome is an inherited form of low-renin hypertension, transmitted with an autosomal dominant pattern. The molecular basis of Liddle syndrome resides in germline mutations of the SCNN1A, SCNN1B and SCNN1G genes, encoding the α, ß, and γ-subunits of the epithelial Na⺠channel (ENaC), respectively. To date, 31 different causative mutations have been reported in 72 families from four continents. The majority of the substitutions cause an increased expression of the channel at the distal nephron apical membrane, with subsequent enhanced renal sodium reabsorption. The most common clinical presentation of the disease is early onset hypertension, hypokalemia, metabolic alkalosis, suppressed plasma renin activity and low plasma aldosterone. Consequently, treatment of Liddle syndrome is based on the administration of ENaC blockers, amiloride and triamterene. Herein, we discuss the genetic basis, clinical presentation, diagnosis and treatment of Liddle syndrome. Finally, we report a new case in an Italian family, caused by a SCNN1B p.Pro618Leu substitution.
Asunto(s)
Canales Epiteliales de Sodio/genética , Síndrome de Liddle/diagnóstico , Adolescente , Humanos , Síndrome de Liddle/tratamiento farmacológico , Síndrome de Liddle/genética , Masculino , Mutación Missense , FenotipoRESUMEN
BACKGROUND: The study aimed to analyze genes involved in Mendelian forms of low-renin hypertension in Chinese early-onset hypertensive patients. METHODS: A panel of nine genes, namely SCNN1B, SCNN1G, WNK1, WNK4, KLHL3, CUL3, nuclear receptor subfamily 3, group C (NR3C)1, NR3C2, and HSD11B2 were screened by targeted resequencing in 260 Chinese early-onset hypertensive patients. Additionally, exon 13 of both SCNN1B and SCNN1G was sequenced in an independent cohort of 506 Chinese early-onset hypertensive patients. RESULTS: About 81 nonrare and 41 rare variants were, respectively, detected in 221 (85.0%) and 39 (15.0%) patients from the cohort of 260. Of the total 766 patients, those with rare variants in exon 13 of either SCNN1B or SCNN1G had a significantly earlier onset of hypertension (24.7â±â7.5 vs. 29.0â±â7.7 years, Pâ=â0.015) and lower serum potassium (3.57â±â0.59 vs. 3.96â±â0.41âmmol/l, Pâ=â0.007) than those without rare variants. However, other identified rare variants had no effects on clinical expression. Seven patients (0.91%) were diagnosed with Liddle's syndrome, and the Liddle's syndrome prevalence was 1.72% among the 407 patients with hypertension diagnosed before the age of 30. Genetic screening of the probands' relatives identified 10 additional Liddle's syndrome patients. Treatment of Liddle's syndrome patients with amiloride resulted in normalization of both blood pressure and serum potassium. CONCLUSION: Liddle's syndrome appears to be the most common low-renin Mendelian hypertension in young Chinese hypertensive patients. Sequencing exon 13 of both SCNN1B and SCNN1G is highly advisable in patients with early-onset and low-renin hypertension.
Asunto(s)
Pueblo Asiatico/genética , Hipertensión/sangre , Hipertensión/genética , Síndrome de Liddle/diagnóstico , Renina/sangre , 11-beta-Hidroxiesteroide Deshidrogenasa de Tipo 2/genética , Proteínas Adaptadoras Transductoras de Señales , Adolescente , Adulto , Edad de Inicio , Amilorida/uso terapéutico , Secuencia de Bases , Presión Sanguínea , Proteínas Portadoras/genética , Proteínas Cullin/genética , Diuréticos/uso terapéutico , Canales Epiteliales de Sodio/genética , Exones , Femenino , Variación Genética , Humanos , Hipertensión/diagnóstico , Hipopotasemia , Síndrome de Liddle/sangre , Síndrome de Liddle/tratamiento farmacológico , Síndrome de Liddle/genética , Masculino , Proteínas de Microfilamentos , Potasio/sangre , Proteínas Serina-Treonina Quinasas/genética , Receptores de Glucocorticoides/genética , Receptores de Mineralocorticoides/genética , Proteína Quinasa Deficiente en Lisina WNK 1/genética , Adulto JovenRESUMEN
Pseudohyperaldosteronism is characterized by a clinical picture of hyperaldosteronism with suppression of renin and aldosterone. It can be due to endogenous or exogenous substances that mimic the effector mechanisms of aldosterone, leading not only to alterations of electrolytes and hypertension, but also to an increased inflammatory reaction in several tissues. Enzymatic defects of adrenal steroidogenesis (deficiency of 17α-hydroxylase and 11ß-hydroxylase), mutations of mineralocorticoid receptor (MR) and alterations of expression or saturation of 11-hydroxysteroid dehydrogenase type 2 (apparent mineralocorticoid excess syndrome, Cushing's syndrome, excessive intake of licorice, grapefruits or carbenoxolone) are the main causes of pseudohyperaldosteronism. In these cases treatment with dexamethasone and/or MR-blockers is useful not only to normalize blood pressure and electrolytes, but also to prevent the deleterious effects of prolonged over-activation of MR in epithelial and non-epithelial tissues. Genetic alterations of the sodium channel (Liddle's syndrome) or of the sodium-chloride co-transporter (Gordon's syndrome) cause abnormal sodium and water reabsorption in the distal renal tubules and hypertension. Treatment with amiloride and thiazide diuretics can respectively reverse the clinical picture and the renin aldosterone system. Finally, many other more common situations can lead to an acquired pseudohyperaldosteronism, like the expansion of volume due to exaggerated water and/or sodium intake, and the use of drugs, as contraceptives, corticosteroids, ß-adrenergic agonists and FANS. In conclusion, syndromes or situations that mimic aldosterone excess are not rare and an accurate personal and pharmacological history is mandatory for a correct diagnosis and avoiding unnecessary tests and mistreatments.
Asunto(s)
Aldosterona/sangre , Hiperaldosteronismo/sangre , Hipertensión/sangre , Sistema Renina-Angiotensina , Biomarcadores/sangre , Síndrome de Cushing/sangre , Síndrome de Cushing/tratamiento farmacológico , Síndrome de Cushing/etiología , Dexametasona/uso terapéutico , Dieta/efectos adversos , Predisposición Genética a la Enfermedad , Glucocorticoides/uso terapéutico , Humanos , Hiperaldosteronismo/tratamiento farmacológico , Hiperaldosteronismo/etiología , Hiperaldosteronismo/genética , Hipertensión/tratamiento farmacológico , Hipertensión/etiología , Hipertensión/genética , Síndrome de Liddle/sangre , Síndrome de Liddle/tratamiento farmacológico , Síndrome de Liddle/genética , Antagonistas de Receptores de Mineralocorticoides/uso terapéutico , Fenotipo , Sistema Renina-Angiotensina/efectos de los fármacos , Factores de Riesgo , Inhibidores de los Simportadores del Cloruro de Sodio/uso terapéutico , Regulación hacia ArribaRESUMEN
Hypertension in paediatric age group is commonly secondary to a known cause. It is crucial to identify the cause of hypertension and treat it before development of any associated complications to prevent morbidity and mortality. Paediatric Hypertension is one of the important clinical finding in a child with certain clinical syndrome. We are presenting a case of a 10 month old child presenting with hypertension and hypokalaemia, after excluding all identifiable causes and her positive response to therapy, that is amiloride, along with supportive biochemical data she was diagnosed as a case of monogenic type of hypertension known as Liddle's syndrome.
Asunto(s)
Síndrome de Liddle/diagnóstico , Amilorida/uso terapéutico , Bloqueadores del Canal de Sodio Epitelial/uso terapéutico , Femenino , Humanos , Lactante , Síndrome de Liddle/tratamiento farmacológicoAsunto(s)
Síndrome de Liddle/diagnóstico , Síndrome de Liddle/patología , Fenotipo , Factores de Edad , Anciano de 80 o más Años , Femenino , Humanos , Hipertensión/diagnóstico , Hipertensión/patología , Hipopotasemia/diagnóstico , Hipopotasemia/patología , Síndrome de Liddle/tratamiento farmacológico , Debilidad Muscular/diagnóstico , Debilidad Muscular/patología , Triantereno/uso terapéuticoRESUMEN
Liddle's syndrome, an autosomal dominant form of monogenic hypertension, is characterized by salt-sensitive hypertension with early penetrance, hypokalemia, metabolic alkalosis, suppression of plasma rennin activity and aldosterone secretion, and a clear-cut response to epithelial sodium channel (ENaC) blockers but not spironolactone therapy. Our understanding of ENaCs and Na(+) transport defects has expanded greatly over the past two decades and provides detailed insight into the molecular basis of Liddle's syndrome. In this review, we offer an overview of recent advances in understanding the molecular genetics of Liddle's syndrome, involving mutation analysis, molecular mechanisms and genetic testing. The ENaC in the distal nephron is composed of α, ß and γ subunits that share similar structures. Mutations associated with Liddle's syndrome are positioned in either ß or γ subunits and disturb or truncate a conserved proline-rich sequence (i.e., PY motif), leading to constitutive activation of the ENaC. Genetic testing has made it possible to make accurate diagnoses and develop tailored therapies for mutation carriers.
Asunto(s)
Síndrome de Liddle/genética , Síndrome de Liddle/metabolismo , Biología Molecular/métodos , Canales Epiteliales de Sodio/genética , Canales Epiteliales de Sodio/metabolismo , Pruebas Genéticas , Humanos , Síndrome de Liddle/diagnóstico , Síndrome de Liddle/tratamiento farmacológicoRESUMEN
Liddle's syndrome is a rare cause of secondary hypertension. Identification of this disorder is important because treatment differs from other forms of hypertension. We report an interesting case of a 35-year-old lady, a known diabetic and hypertensive patient, who presented with features of hypertensive encephalopathy. The family history was unremarkable. Past treatment with various combinations of antihypertensive medications including spironolactone, all at high doses, failed to control her blood pressure. Upon evaluation, the patient had hypokalemic alkalosis, low 24-h urine potassium and suppressed plasma renin activity. Although these findings were similar to hyperaldosteronism, plasma aldosterone was lower than the normal range. Blood pressure decreased markedly after administration of amiloride. Along with hyporeninemic hypo-aldosteronism, the non-responsiveness to spironolactone and good response to amiloride established the diagnosis of Liddle's syndrome.
Asunto(s)
Encefalopatía Hipertensiva/etiología , Síndrome de Liddle/complicaciones , Adulto , Amilorida/uso terapéutico , Antihipertensivos/uso terapéutico , Presión Sanguínea/efectos de los fármacos , Diuréticos/uso terapéutico , Femenino , Humanos , Encefalopatía Hipertensiva/diagnóstico , Encefalopatía Hipertensiva/tratamiento farmacológico , Síndrome de Liddle/diagnóstico , Síndrome de Liddle/tratamiento farmacológico , Resultado del TratamientoRESUMEN
Medications can cause a tubulointerstitial insult leading to acute kidney injury through multiple mechanisms. Acute tubular injury, a dose-dependent process, occurs due to direct toxicity on tubular cells. Acute interstitial nephritis characterized by interstitial inflammation and tubulitis develops from drugs that incite an allergic reaction. Other less common mechanisms include osmotic nephrosis and crystalline nephropathy. The latter complication is rare but has been associated with several drugs, such as sulfadiazine, indinavir, methotrexate, and ciprofloxacin. Triamterene crystalline nephropathy has been reported only rarely, and its histologic characteristics are not well characterized. We report 2 cases of triamterene crystalline nephropathy, one of which initially was misdiagnosed as 2,8-dihydroxyadenine crystalline nephropathy.
Asunto(s)
Hidroclorotiazida/efectos adversos , Riñón/patología , Insuficiencia Renal Crónica , Triantereno/efectos adversos , Privación de Tratamiento , Antihipertensivos/administración & dosificación , Antihipertensivos/efectos adversos , Biopsia , Creatinina/sangre , Errores Diagnósticos/prevención & control , Combinación de Medicamentos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/diagnóstico , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/etiología , Femenino , Técnica del Anticuerpo Fluorescente , Tasa de Filtración Glomerular , Humanos , Hidroclorotiazida/administración & dosificación , Síndrome de Liddle/tratamiento farmacológico , Enfermedad de Meniere/tratamiento farmacológico , Persona de Mediana Edad , Insuficiencia Renal Crónica/inducido químicamente , Insuficiencia Renal Crónica/patología , Insuficiencia Renal Crónica/fisiopatología , Insuficiencia Renal Crónica/terapia , Resultado del Tratamiento , Triantereno/administración & dosificaciónRESUMEN
Hypokalemia is common and can be associated with serious adverse consequences, including paralysis, ileus, cardiac arrhythmias, and death. As a result, the body maintains serum potassium concentration within very narrow limits by tightly regulated feedback and feed-forward systems. Whereas the consequences of symptomatic hypokalemia and severe potassium depletion are well appreciated, chronic mild hypokalemia can accelerate the progression of chronic kidney disease, exacerbate systemic hypertension, and increase mortality. Persistent hypokalemia may reflect total-body potassium depletion or increased renal potassium clearance. In a patient with simple potassium depletion, potassium replacement therapy should correct serum potassium concentration, but may have little effect when renal potassium clearance is abnormally increased from potassium wasting. In such cases, the addition of potassium-sparing diuretics might be helpful. Serum potassium concentration is an inaccurate marker of total-body potassium deficit. Mild hypokalemia may be associated with significant total-body potassium deficits and conversely, total-body potassium stores can be normal in patients with hypokalemia due to redistribution. The speed and extent of potassium replacement should be dictated by the clinical picture and guided by frequent reassessment of serum potassium concentration(.) The goals of therapy should be to correct a potassium deficit, if present, without provoking hyperkalemia. Oral replacement is preferred except when there is no functioning bowel or in the setting of electrocardiogram changes, neurologic symptoms, cardiac ischemia, or digitalis therapy.
Asunto(s)
Hipertensión/diagnóstico , Hipopotasemia/diagnóstico , Síndrome de Liddle/diagnóstico , Cloruro de Potasio/uso terapéutico , Desequilibrio Hidroelectrolítico/diagnóstico , Adulto , Amilorida/uso terapéutico , Femenino , Estudios de Seguimiento , Humanos , Hipertensión/tratamiento farmacológico , Hipopotasemia/tratamiento farmacológico , Síndrome de Liddle/tratamiento farmacológico , Sistema Renina-Angiotensina/fisiología , Medición de Riesgo , Desequilibrio Hidroelectrolítico/tratamiento farmacológicoRESUMEN
We describe here the interesting case of a 73-year-old hypertensive man with pseudoaldosteronism. He had been taking glycyrrhizin at a dose of 75 mg/day for 12 years because of mild liver damage, but had never experienced any previous symptoms associated with hypokalemia. He was referred to our hospital because of hypokalemic tetraparesis and rhabdomyolysis. At that time, we noted mineralocorticoid excess characterized by hypokalemia due to urinary K loss, exacerbation of hypertension due to increased tubular Na reabsorption, metabolic alkalosis, and suppression of both plasma renin activity and plasma aldosterone concentration. His urinary free cortisol excretion rate and the urinary ratio of free cortisol to free cortisone were markedly elevated. Thus we diagnosed pseudoaldosteronism that was related to the long-term use of glycyrrhizin. When he developed pseudoaldosteronism, he also contracted pneumonia, and exhibited elevated levels of serum cortisol and creatinine clearance (CCr) as well as hypouricemia, hypocalcemia, and hypophosphatemia. All normalized after the recovery from pneumonia and the administration of spironolactone. The extracellular volume expansion associated with increased tubular Na reabsorption by the aldosterone-sensitive distal nephron and the resulting increase in CCr caused an inhibition of proximal tubular reabsorption of uric acid, Ca, and inorganic phosphate, leading to their renal loss and therefore hypouricemia, hypocalcemia, and hypophosphatemia, respectively. In this patient, the increased circulating cortisol associated with the stress of inflammation caused by pneumonia triggered the development of pseudoaldosteronism.